Precision Historical Financial Ratios
DTIL Stock | USD 4.54 0.01 0.22% |
Precision BioSciences is promptly reporting on over 100 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.48 or Days Sales Outstanding of 8.57 will help investors to properly organize and evaluate Precision BioSciences financial condition quickly.
Precision |
About Precision Financial Ratios Analysis
Precision BioSciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Precision BioSciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Precision financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Precision BioSciences history.
Precision BioSciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Precision BioSciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Precision BioSciences sales, a figure that is much harder to manipulate than other Precision BioSciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Precision BioSciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Precision BioSciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.At this time, Precision BioSciences' Interest Coverage is quite stable compared to the past year. ROE is expected to rise to 0.13 this year, although the value of Days Sales Outstanding will most likely fall to 8.57.
2010 | 2024 | 2025 (projected) | Payables Turnover | 13.79 | 3.2 | 3.04 | Days Of Inventory On Hand | 306.14 | 275.53 | 244.91 |
Precision BioSciences fundamentals Correlations
Click cells to compare fundamentals
Precision BioSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Precision BioSciences fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Price To Sales Ratio | 17.87 | 3.76 | 4.17 | 0.86 | 0.38 | 0.36 | |
Ptb Ratio | 9.77 | 4.76 | 1.73 | 2.23 | 0.46 | 0.48 | |
Days Sales Outstanding | 150.3 | 1.54 | 10.47 | 95.87 | 9.02 | 8.57 | |
Book Value Per Share | 25.61 | 46.6 | 20.63 | 4.91 | 8.25 | 7.84 | |
Free Cash Flow Yield | (0.21) | (0.0384) | (0.47) | (2.05) | (2.25) | (2.14) | |
Operating Cash Flow Per Share | (50.38) | (5.55) | (15.62) | (21.9) | (8.55) | (8.98) | |
Stock Based Compensation To Revenue | 0.57 | 0.14 | 0.76 | 0.29 | 0.18 | 0.26 | |
Capex To Depreciation | 0.51 | 0.57 | 0.37 | 0.28 | 0.0546 | 0.0519 | |
Pb Ratio | 9.77 | 4.76 | 1.73 | 2.23 | 0.46 | 0.48 | |
Ev To Sales | 14.6 | 2.59 | (2.31) | (0.89) | (0.85) | (0.81) | |
Free Cash Flow Per Share | (53.28) | (8.51) | (16.75) | (22.49) | (8.59) | (9.02) | |
Roic | (0.38) | (1.08) | (0.22) | (0.61) | 0.0578 | 0.0607 | |
Net Income Per Share | (62.85) | (15.8) | (41.95) | (15.96) | 1.05 | 1.1 | |
Sales General And Administrative To Revenue | 1.48 | 0.34 | 1.65 | 0.8 | 0.51 | 0.49 | |
Research And Ddevelopement To Revenue | 4.04 | 1.0 | 3.34 | 1.1 | 0.87 | 0.82 | |
Capex To Revenue | 0.21 | 0.0502 | 0.13 | 0.0468 | 0.003639 | 0.003457 | |
Cash Per Share | 51.77 | 73.44 | 64.7 | 30.37 | 12.63 | 12.0 | |
Pocfratio | (4.97) | (40.02) | (2.29) | (0.5) | (0.45) | (0.42) | |
Capex To Operating Cash Flow | (0.0576) | (0.53) | (0.0725) | (0.0271) | (0.004278) | (0.004491) | |
Pfcf Ratio | (4.7) | (26.07) | (2.13) | (0.49) | (0.44) | (0.42) | |
Income Quality | 0.8 | 0.35 | 0.41 | 1.37 | (8.15) | (7.75) | |
Roe | (0.6) | (2.45) | (0.34) | (2.03) | (3.25) | 0.13 | |
Ev To Operating Cash Flow | (4.06) | (27.62) | 1.27 | 0.52 | 1.0 | 0.95 | |
Pe Ratio | (3.98) | (14.05) | (0.85) | (0.69) | 3.63 | 3.81 | |
Return On Tangible Assets | (0.73) | (0.15) | (0.52) | (0.38) | 0.0528 | 0.0554 | |
Ev To Free Cash Flow | (3.84) | (18.0) | 1.18 | 0.5 | 1.0 | 0.95 | |
Earnings Yield | (0.25) | (0.0712) | (1.18) | (1.46) | 0.28 | 0.29 | |
Intangibles To Total Assets | 0.009144 | 0.009683 | 0.00566 | 0.002503 | 0.004561 | 0.0068 | |
Net Debt To E B I T D A | 0.8 | 6.64 | 2.59 | 2.67 | (6.25) | (5.94) | |
Current Ratio | 2.46 | 4.5 | 3.34 | 2.73 | 6.34 | 6.49 | |
Tangible Book Value Per Share | 24.82 | 45.56 | 20.17 | 4.81 | 8.16 | 7.75 | |
Receivables Turnover | 2.43 | 236.74 | 34.86 | 3.81 | 40.46 | 38.43 | |
Shareholders Equity Per Share | 25.61 | 46.6 | 20.63 | 4.91 | 8.25 | 7.84 | |
Capex Per Share | 2.9 | 2.97 | 1.13 | 0.59 | 0.0366 | 0.0348 | |
Graham Net Net | (3.2) | 16.57 | 5.51 | (3.81) | 1.11 | 1.06 | |
Revenue Per Share | 14.0 | 59.06 | 8.57 | 12.68 | 10.05 | 11.79 | |
Interest Debt Per Share | 6.06 | 4.73 | 9.61 | 8.72 | 0.45 | 0.43 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.04 | Revenue Per Share | Quarterly Revenue Growth (0.96) | Return On Assets | Return On Equity |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.